Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Novasys Medical

This article was originally published in The Gray Sheet

Executive Summary

Non-surgical treatment for female stress urinary incontinence gains expanded R&D funding via $13 mil. private placement of preferred stock. Delphi Ventures, Onset Ventures, Alloy Ventures, Affinity Capital Advisors and Rothschild Bioscience Managers participated in the financing. A pilot study of 41 women with SUI in Chile and Mexico has been completed, and clinical results are being analyzed, Sunnyvale, California-based Novasys says. The radiofrequency catheter-based, bladder outlet remodeling device works by increasing bladder outlet resistance

Latest Headlines
See All
UsernamePublicRestriction

Register

MT015553

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel